CD4 antibody is expressed in a subset of T-cells and has been reported to be found in approximately 80% of thymocytes and in 45% of peripheral blood lymphocytes. CD4 is expressed in the majority of T-cell lymphomas, including mycosis fungoides. Multiple studies have concluded that CD4+CD25+ regulatory T cells possess immunosuppressive activity and are commonly observed in elevated proportions in several types of cancers, including non-small cell lung cancer, breast cancer, prostate, and ovarian cancer. Recent studies have concluded that CD4 positivity in regulatory T cells may be associated with a poor prognostic outcome in prostate cancer patients.
1. Davidsson S, et al. Mod Pathol. 2013 Mar; 26(3):448-55. 2. Woo EY, et al. Cancer Res. 2001 Jun; 61(12):4766-72. 3. Nakamura K, Kitani A, Strober W. J Exp Med. 2001 Sep; 194(5):629-44.4. Rüdiger T, et al. Am
J Surg Pathol 2000 Jan; 24(1):117-22.